Information regarding Lung Cancer Treatment

The request was successful.

Dear South Tyneside and Sunderland NHS Foundation Trust,

I would like to ask the following question regarding lung cancer treatment.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

• Afatinib
• Alectinib
• Atezolizumab monotherapy
• Atezolizumab in combination
• Bevacizumab
• Brigatinib
• Capmatenib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Docetaxel monotherapy
• Durvalumab
• Erlotinib
• Gefitinib
• Gemcitabine
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Paclitaxel
• Pembrolizumab monotherapy
• Pembrolizumab in combination
• Pemetrexed with Carboplatin/Cisplatin
• Tepotinib
• Vinorelbine with Cisplatin/Carboplatin
• Any other SACT
• Palliative care only

Thank you for taking the time to answer this question and I look forward to hearing from you.

Yours faithfully,

David Elder

FREEDOMOFINFORMATION (SOUTH TYNESIDE AND SUNDERLAND NHS FOUNDATION TRUST),

​Thank you for your request under the Freedom of Information Act 2000.
This email is acknowledgement that your request has been received by South
Tyneside and Sunderland NHS Foundation Trust, and a response will be
provided in due course.

As this is only a standard acknowledgement of your request at this moment
we are unaware of any fees, charges or exemptions that may be applied to
your request.  If during the course of processing your application it
becomes clear that fees will apply, we will inform you of this.  In the
event that costs are applicable, no information will be provided unless
the costs are paid within three months of us informing you.  In the event
that some or all of the information you have requested is exempt from
disclosure, we will notify you of this.  

We will also contact you if, during the process to locate and supply the
information, it emerges that we do not have sufficient detail to be able
to do so, or we are unclear exactly what it is that you have requested. 

If some or all of the information you are requesting is accessible via the
internet we will direct you to this.  If this happens and you do not have
internet access please let us know.  

Kind regards
Freedom of Information Office
South Tyneside and Sunderland NHS Foundation Trust

show quoted sections

FREEDOMOFINFORMATION (SOUTH TYNESIDE AND SUNDERLAND NHS FOUNDATION TRUST),

1 Attachment

Thank you for your request for information under the Freedom of
Information Act 2000.  Please find attached the response from South
Tyneside and Sunderland NHS Foundation Trust. 

To assist the Trust in improving its service, it would be helpful if you
could provide feedback by completing a short [1]feedback form.  

 

If you are unhappy with the way your request for information has been
handled, you can request a review by writing to: Freedom of Information
Office, South Tyneside and Sunderland NHS Foundation Trust, Harton Wing,
Harton Lane, South Shields, NE34 0PL or via email
at [2][South Tyneside and Sunderland NHS Foundation Trust request email].  

 

If you remain dissatisfied with the handling of your request or complaint,
you have a right to appeal to the Information Commissioner at: The
Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow,
Cheshire, SK9 5AF. Telephone: 0303 123 1113
Website: [3]www.ico.org.uk.  There is no charge for making an appeal.   

 

The Commissioner’s Office will not normally hear a complaint until the
internal complaints procedure has been completed.   

Kind regards

Freedom of Information Office

South Tyneside and Sunderland NHS Foundation Trust

Email: [4][South Tyneside and Sunderland NHS Foundation Trust request email]

Web: [5]www.stsft.nhs.uk

 

IMPORTANT NOTICE: This email and any attachments are intended solely for
the use of the intended recipient and may contain privileged and
confidential information.  If you are not the intended recipient, you are
hereby notified that any distribution or copying is strictly prohibited. 
If you receive this e-mail in error, please notify us as soon as possible
and destroy the document. Any views or opinions expressed are solely those
of the author and do not necessarily represent those of South Tyneside and
Sunderland NHS Foundation Trust. 

 

Please note that South Tyneside and Sunderland NHS Foundation Trust was
formed on 1 April 2019 following the merger of City Hospitals Sunderland
NHS Foundation Trust and South Tyneside NHS Foundation Trust.  Information
requests prior to this date will be provided separately for the previous
Trusts.

══════════════════════════════════════════════════════════════════════════

From: David Elder <[FOI #850566 email]>
Sent: 01 April 2022 11:02
To: FREEDOMOFINFORMATION (SOUTH TYNESIDE AND SUNDERLAND NHS FOUNDATION
TRUST) <[South Tyneside and Sunderland NHS Foundation Trust request email]>
Subject: Freedom of Information request - Information regarding Lung
Cancer Treatment
 
Dear South Tyneside and Sunderland NHS Foundation Trust,

I would like to ask the following question regarding lung cancer
treatment.

The purpose of these questions is to understand the variability of
treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available),
how many metastatic non-small cell lung cancer (NSCLC) patients were
treated with any of the following:

•       Afatinib

•       Alectinib

•       Atezolizumab monotherapy

•       Atezolizumab in combination

•       Bevacizumab

•       Brigatinib

•       Capmatenib

•       Ceritinib

•       Crizotinib

•       Dacomitinib

•       Dabrafenib with Trametinib

•       Docetaxel monotherapy

•       Durvalumab

•       Erlotinib

•       Gefitinib

•       Gemcitabine

•       Nintedanib with Docetaxel

•       Nivolumab

•       Osimertinib

•       Paclitaxel

•       Pembrolizumab monotherapy

•       Pembrolizumab in combination

•       Pemetrexed with Carboplatin/Cisplatin

•       Tepotinib

•       Vinorelbine with Cisplatin/Carboplatin

•       Any other SACT

•       Palliative care only

Thank you for taking the time to answer this question and I look forward
to hearing from you.

Yours faithfully,

David Elder

-------------------------------------------------------------------

Please use this email address for all replies to this request:

[FOI #850566 email]

Is [South Tyneside and Sunderland NHS Foundation Trust request email] the wrong address for Freedom of
Information requests to South Tyneside and Sunderland NHS Foundation
Trust? If so, please contact us using this form:

[6]https://www.whatdotheyknow.com/change_re...

Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:

[7]https://www.whatdotheyknow.com/help/offi...

For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:

[8]https://www.whatdotheyknow.com/help/ico-...

Please note that in some cases publication of requests and responses will
be delayed.

If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.

show quoted sections